Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-13
2005-12-13
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C436S500000
Reexamination Certificate
active
06974793
ABSTRACT:
A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.
REFERENCES:
patent: 5667808 (1997-09-01), Johnson et al.
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5980945 (1999-11-01), Ruiz
patent: 6007843 (1999-12-01), Drizen et al.
patent: 6011011 (2000-01-01), Hageman
patent: 6022554 (2000-02-01), Lee et al.
patent: WO94/21300 (1994-09-01), None
Ahren, B.;Cholinergic and VIPergic Effects on Thyroid Hormone Secretion in the Mouse; Peptides;6:585-589 (1985).
Amenta, F., et al.;Cholinergic Nerves in the Thyroid Gland; Cell and Tissue Res.;195:367-370 (1978).
Aoki, K.R.;Preclinical Update on BOTOX®(botulinum Toxin Type A)-Purified Neurotoxin Complex Relative to other Botulinum Neurotoxin Preparations;Eur. J. Neurol; 6(Suppl 4):S3-S10; (1999).
Boyd, R.S., et al.;The Effect of Botulinum Neurotoxin-B on Insulin Release from a B-Cell Line; Movement Disorders;vol. 10, No. 3; Item 19; 376 (1995).
Boyd, R.S., et al.;The Insulin Secreting B-Cell Line HIT-15 Contains SNAP-25 Which is a Target for Botulinum Neurotoxin-A; Movement Disorders;vol. 10, No. 3; Item 20; 376 (1995).
Brandi, M.L., et al.;Interaction of VIPergic and Cholinergic Receptors in Human Thyroid Cell; Peptides;8:893-897 (1987).
Braverman, L.E. (Editor);Diseases of the Thyroid;Humana Press; p. 157 (1997).
Cardinali, D.P., et al.;Peripheral Neuroendocrinology of the Cervical Autonomic Nervous System; Brazilian J. Med. Biol. Res.;27(3):573-599 (1994).
Fauci, A.S., et al. (Editors);Harrison's Principles of Internal Medicine,14thEdition; McGraw-Hill (1998).
Garry, M.G., et al.;Evaluation of the Efficacy of a Bioerodible Bupivacaine Polymer System on Antinociception and Inflammatory Mediator Release; Pain;82(1);49-55 (1999).
Gonelle-Gispert, C., et al.;SNAP-25A AND-25B Isoforms are Both Expressed in Insulin-Secreting Cells and Can Function in Insulin Secretion; Biochem. J.;339:159-165 (1999).
Huffman, L.J., et al.;Muscarinic Modulation of the Vasodilatory Effects of Vasodilatory Effects of Vasoactive Intestinal Peptide at the Rat Thyroid Gland; Neuroendocrinology;53:69-74 (1991).
Lakomy, M., et al.;Acetylcholine Esterase Positive Nerves in Swine Thyroid; Z. mikrosk.-anat. Forsch., Leipzig100, 1, S. 34-38 (1986).
Laskawi, R., et al.;Up-to-Date Report of Botulinum Toxin Type A Treatment in Patients with Gustatory Sweating(Frey's Syndrome);Laryngoscope108; 381-384 (Mar. 1998).
Longley, R.S., et al.;Effect of the Parasympathetic System on Calcitonin Secretion; Clin Res;27:657A (1979).
Lopez-Muniz, A., et al.;Etude des terminaisons nerveuses au contact des cellules parafolliculaires de la thyroide; Annales d'Endocrinologie(Paris); 59:3-8 (1998).
Melander, A., et al.;Presence and Influence of Cholinergic Nerves in the Mouse Thyroid; Endocrinology;105(1):7-9 (1979).
Mercadante, S., et al.;Celiac Plexus Block: A Reappraisal; Regional Anesthesia and Pain Medicine;23(1):37-48 (Jan.-Feb. 1998).
Powell, E.M., et al.;Controlled Release of Nerve Growth Factor from a Polymeric Implant; Brain Res;515(1-2):309-311 (1990).
Rao, J.K., et al.;Implantable Controlled Delivery Systems for Proteins Based on Collagen—pHEMA Hydrogels; Biomaterials;15(5):383-389 (1994).
Ragona, R.M., et al.;Management of Parotid Sialocete with Botulinum Toxin; Laryngoscope109; 1344-1346 (Aug. 1999).
Schantz, E.J. et al.;Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; Microbiological Reviews;vol. 56, No. 1; 80-99 (Mar. 1992).
Singh, B.R.;Critical Aspects of Bacterial Protein Toxins; Natural Toxins II;Plenum Press, New York; pp. 63-84 (1996).
Stern, J.E., et al.;Influence of the Autonomic Nervous System on Calcium Homeostasis in the Rat; Biol Signals;3:15-25 (1994).
Stern, J.E., et al.;Parasympathetic Control of Parathyroid Hormone and Calcitonin Secretion in Rats; Journal of the Autonomic Nervous System;48:45-53 (1994).
Stevens, P.D., et al.;Managing Chronic Pancreatitis Pain: A Block in Time; AJG;94(4):872-874 (1999).
Unger, J., et al.;Mechanism of Cholinergic Inhibition of Dog Thyroid Secretion In Vitro; Endocrinology;114:1266-1271 (1984).
Williams, G.A., et al.;Effect of the Parasympathetic System on Secretion of Parathyroid Hormone; Metabolism;vol. 34, No. 7; 612-615 (Jul. 1985).
Allergan Inc.
Baran Robert J.
Donovan Stephen
Liu Samuel Wei
Voet Martin A.
LandOfFree
Method for treating primary hyperparathyroid disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating primary hyperparathyroid disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating primary hyperparathyroid disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477715